VEC + cisplatin

VEC + cisplatin is a combination chemotherapy regimen that includes vinblastine, epidoxorubicin, and cisplatin. This combination is also known as M-VEC (methotrexate, vinblastine, epidoxorubicin, and cisplatin), where epidoxorubicin has been substituted for adriamycin[2]. The regimen is used in the treatment of various cancers, particularly bladder cancer. ## Composition and Mechanism of Action The combination works through multiple mechanisms: - **Cisplatin**: A platinum-based chemotherapy agent that forms platinum-DNA adducts, interfering with DNA replication and transcription, leading to cell death[1][4]. - **Vinblastine**: A vinca alkaloid that binds to tubulin and inhibits microtubule formation, preventing cell division. - **Epidoxorubicin**: An anthracycline antibiotic that intercalates with DNA and inhibits topoisomerase II, preventing DNA replication. This multi-drug approach targets cancer cells through different mechanisms, potentially creating synergistic effects that enhance overall efficacy. ## Clinical Applications VEC + cisplatin is primarily used in the treatment of: - Bladder cancer[2] - Potentially other carcinomas where cisplatin combinations have shown efficacy Cisplatin is known to have synergistic effects with many other drugs, including vinorelbine, gemcitabine, and etoposide, making it a valuable component in combination chemotherapy regimens[1]. ## Administration The drugs in this combination are typically administered intravenously. Patients may receive treatment through: - A central line - A PICC line - A portacath - A cannula inserted into a vein in the arm[6] Treatment is usually given in cycles, with specific dosing schedules determined by the patient's condition, cancer type, and response to treatment. ## Side Effects As with most chemotherapy combinations, VEC + cisplatin can cause various side effects. Patients should be monitored for: - Myelosuppression (decreased blood cell production) - Nausea and vomiting - Nephrotoxicity (kidney damage) - Neurotoxicity - Cardiotoxicity (particularly from epidoxorubicin) - Risk of tissue damage if the drugs leak out of the vein during administration (extravasation)[6] This combination represents one of many cisplatin-based regimens used in cancer treatment, with specific combinations chosen based on the type of cancer being treated and patient-specific factors.

Other names

M-VEC (modified)